Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
06 mars 2019 08h03 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to...
Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
06 mars 2019 08h02 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement...
Galectin Therapeutics to Present at Berenberg NASH Day in New York
25 févr. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
15 janv. 2019 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest...
Galectin Therapeutics Announces Extension of $10 Million Line Credit
20 déc. 2018 08h30 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million...
Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
19 nov. 2018 09h19 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
13 nov. 2018 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
15 oct. 2018 10h22 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
15 oct. 2018 08h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
20 sept. 2018 08h00 HE
|
Galectin Therapeutics Inc.
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33%...